Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification

Journal of Hepato-Biliary-Pancreatic Sciences

Volumn 21, Issue 6, 2014, Pages 418-425

  Tsutsumi, Kosuke ^a   Ohtsuka, Takao ^a   Fujino, Minoru ^a   Nakashima, Hiroshi ^b   Aishima, Shinichi ^a   Ueda, Junji ^a   Takahata, Shunichi ^a   Nakamura, Masafumi ^b   Oda, Yoshinao ^a   Tanaka, Masao ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Grading classification; Neural invasion; Pancreatic neuroendocrine tumor; Predictors of recurrence; WHO 2010 classification

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER INCIDENCE; CANCER RECURRENCE; CANCER SURGERY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PANCREATIC NEUROENDOCRINE TUMOR; PATHOLOGIST; PERINEURAL INVASION; RETROSPECTIVE STUDY; RISK FACTOR; TUMOR INVASION; TUMOR VOLUME; WORLD HEALTH ORGANIZATION; ANALYSIS OF VARIANCE; CLASSIFICATION; COHORT ANALYSIS; CONFIDENCE INTERVAL; DISEASE FREE SURVIVAL; EVALUATION STUDY; JAPAN; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REPRODUCIBILITY; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE; YOUNG ADULT;

ADULT; AGED; ANALYSIS OF VARIANCE; COHORT STUDIES; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION; YOUNG ADULT;

EID: 84901286542     PISSN: 18686974     EISSN: 18686982     Source Type: Journal    
DOI: 10.1002/jhbp.47     Document Type: Article

References (28)

1. Klimstra DS, Arnold R, Capella C, Hruban RH, Kloppel G, Komminoth P, et al. Neuroendocrine neoplasms of the pancreas. In:, Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO classification of tumours of the digestive system. Lyon, France: IARC Press; 2010. p. 322-326.
2. Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006; 449: 395-401.
3. Kloppel G, Rindi G, Perren A, Komminoth P, Klimstra DS,. The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement. Virchows Arch. 2010; 456: 595-597.
4. Kloppel G, Couvelard A, Perren A, Komminoth P, McNicol AM, Nilsson O, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology. 2009; 90: 162-166.
5. Boninsegna L, Panzuto F, Partelli S, Capelli P, Delle Fave G, Bettini R, et al. Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections. Eur J Cancer. 2012; 48: 1608-1615.
6. Casadei R, Ricci C, Pezzilli R, Campana D, Tomassetti P, Calculli L, et al. Are there prognostic factors related to recurrence in pancreatic endocrine tumors? Pancreatology. 2010; 10: 33-38.
7. Kim SJ, Kim JW, Oh DY, Han SW, Lee SH, Kim DW, et al. Clinical course of neuroendocrine tumors with different origins (the pancreas, gastrointestinal tract, and lung). Am J Clin Oncol. 2012; 35: 549-556.
8. Tsutsumi K, Ohtsuka T, Mori Y, Fujino M, Yasui T, Aishima S, et al. Analysis of lymph node metastasis in pancreatic neuroendocrine tumors (PNETs) based on the tumor size and hormonal production. J Gastroenterol. 2012; 47: 678-685.
9. Rindi G, Arnold R, Bosman FT, Capella C, Klimstra DS, Kloppel G, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In:, Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO classification of tumours of the digestive system. Lyon, France: IARC Press; 2010. p. 13-14.
10. Imamura M, Komoto I, Ota S,. Changing treatment strategy for gastrinoma in patients with Zollinger-Ellison syndrome. World J Surg. 2006; 30: 1-11.
11. Hochwald SN, Zee S, Conlon KC, Colleoni R, Louie O, Brennan MF, et al. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol. 2002; 20: 2633-2642.
12. Scarpa A, Mantovani W, Capelli P, Beghelli S, Boninsegna L, Bettini R, et al. Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol. 2010; 23: 824-833.
13. Piani C, Franchi GM, Cappelletti C, Scavini M, Albarello L, Zerbi A, et al. Cytological ki-67 in pancreatic endocrine tumours: an opportunity for pre-operative grading. Endocr Relat Cancer. 2008; 15: 175-181.
14. Chatzipantelis P, Konstantinou P, Kaklamanos M, Apostolou G, Salla C,. The role of cytomorphology and proliferative activity in predicting biologic behavior of pancreatic neuroendocrine tumors: a study by endoscopic ultrasound-guided fine-needle aspiration cytology. Cancer Cytopathol. 2009; 117: 211-216.
15. Alexiev BA, Darwin PE, Goloubeva O, Ioffe OB,. Proliferative rate in endoscopic ultrasound fine-needle aspiration of pancreatic endocrine tumors: correlation with clinical behavior. Cancer. 2009; 117: 40-45.
16. Yang Z, Tang LH, Klimstra DS,. Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification. Am J Surg Pathol. 2011; 35: 853-860.
17. Hamilton NA, Liu TC, Cavatiao A, Mawad K, Chen L, Strasberg SS, et al. Ki-67 predicts disease recurrence and poor prognosis in pancreatic neuroendocrine neoplasms. Surgery. 2012; 152: 107-113.
18. Madeira I, Terris B, Voss M, Denys A, Sauvanet A, Flejou JF, et al. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut. 1998; 43: 422-427.
19. Bettini R, Boninsegna L, Mantovani W, Capelli P, Bassi C, Pederzoli P, et al. Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. Ann Oncol. 2008; 19: 903-908.
20. Bilimoria KY, Talamonti MS, Tomlinson JS, Stewart AK, Winchester DP, Ko CY, et al. Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Ann Surg. 2008; 247: 490-500.
21. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG,. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003; 197: 29-37.
22. Elias D, Lasser P, Ducreux M, Duvillard P, Ouellet JF, Dromain C, et al. Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study. Surgery. 2003; 133: 375-382.
23. Norton JA, Warren RS, Kelly MG, Zuraek MB, Jensen RT,. Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery. 2003; 134: 1057-1063.
24. Touzios JG, Kiely JM, Pitt SC, Rilling WS, Quebbeman EJ, Wilson SD, et al. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg. 2005; 241: 776-783.
25. Mayo SC, de Jong MC, Pulitano C, Clary BM, Reddy SK, Gamblin TC, et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol. 2010; 17: 3129-3136.
26. National comprehensive cancer network (NCCN) clinical practice guidelines in oncology. Neuroendocrine tumors, version 1. 2012: http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp#neuroendocrine
27. Welin S, Stridsberg M, Cunningham J, Granberg D, Skogseid B, Oberg K, et al. Elevated plasma chromogranin a is the first indication of recurrence in radically operated midgut carcinoid tumors. Neuroendocrinology. 2009; 89: 302-307.
28. Japan Pancreas Society. General rules for the study of pancreatic cancer, 6th edn. Tokyo: Kanehara; 2009.